The safety and immunogenicity of a CETP vaccine in healthy adults

Atherosclerosis

Volumn 169, Issue 1, 2003, Pages 113-120

  Davidson, Michael H ^a   Maki, Kevin ^a   Umporowicz, Denise ^a   Wheeler, Alistair ^b   Rittershaus, Charles ^b   Ryan, Una ^b  

^a RADIANT RESEARCH   (United States)

^b AVANT Immunotherapeutics Inc   (United States)

Author keywords

Auto antibodies; Cholesterol ester transfer protein (CETP); Vaccine

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIONEUROTIC EDEMA; ANTIGEN BINDING; ARTHRALGIA; ARTICLE; ATHEROGENESIS; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSPEPSIA; EPISTAXIS; FLU LIKE SYNDROME; HEADACHE; HUMAN; IMMUNOGENICITY; INOCULATION; INTERMETHOD COMPARISON; LIBIDO DISORDER; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION TEST; LUNG CONGESTION; MUSCLE FATIGUE; MUSCLE HYPERTROPHY; MYALGIA; NAUSEA; NORMAL HUMAN; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOSINUSITIS; SINGLE DRUG DOSE; SKIN DISCOLORATION; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

EID: 0037630623     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(03)00137-0     Document Type: Article

References (23)

1. Jackevicius C.A., Mamdani M., Tu J.V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. J. Am. Med. Assoc. 288:2002;462-467.
2. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486-97.
3. Tall A.R. Plasma cholesteryl ester transfer protein and high-density lipoproteins: new insights from molecular genetic studies. J. Intern. Med. 237:1995;5-12.
4. Tall A.R. An overview of reverse cholesterol transport. Eur. Heart J. 19:(Suppl. A):1998;A31-A35.
5. Kuivenhoven J.A., Jukema J.W., Zwinderman A.H., de Knijff P., McPherson R., Bruschke A.V., Lie K.I., Kastelein J.J. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The regression growth evaluation statin study group. New Engl. J. Med. 338:1998;86-93.
6. Whitlock M.E., Swenson T.L., Ramakrishnan R., Leonard M.T., Marcel Y.L., Milne R.W., Tall A.R. Monoclonal antibody inhibition of cholesteryl ester transfer protein activity in the rabbit. Effects on lipoprotein composition and high density lipoprotein cholesteryl ester metabolism. J. Clin. Invest. 84:1989;129-137.
7. Brown M.L., Inazu A., Hesler C.B., Agellon L.B., Mann C., Whitlock M.E., Marcel Y.L., Milne R.W., Koizumi J., Mabuchi H., et al. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature. 342:1989;448-451.
8. Rittershaus C.W., Miller D.P., Thomas L.J., Picard M.D., Honan C.M., Emmett C.D., Pettey C.L., Adari H., Hammond R.A., Beattie D.T., Callow A.D., Marsh H.C., Ryan U.S. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20:2000;2106-2112.
9. Delves P.J., Lund T., Roitt I.M. Antifertility vaccines. Trends Immunol. 23:2002;213-219.
10. Talwar G.P., Singh O.M., Gupta S.K., Hasnain S.E., Pal R., Majumbar S.S., Vrati S., Mukhopadhay A., Srinivasan J., Deshmukh U., Ganga S., Mandokhot A., Gupta A. The HSD-hCG vaccine prevents pregnancy in women: feasibility study of a reversible safe contraceptive vaccine. Am. J. Reprod. Immunol. 37:1997;153-160.
11. Brett B.T., Smith S.C., Bouvier C.V., Michaeli D., Hochhauser D., Davidson B.R., Kurzawinski T.R., Watkinson A.F., Van Someren N., Pounder R.E., Caplin M.E. Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J. Clin. Oncol. 20:2002;4225-4231.
12. Data on file. AVANT Immunotherapeutics, Inc., Needham, MA.
13. Hesler C.B., Tall A.R., Swenson T.L., Weech P.K., Marcel Y.L., Milne R.W. Monoclonal antibodies to the Mr 74 000 cholesteryl ester transfer protein neutralize all of the cholesteryl ester and triglyceride transfer activities in human plasma. J. Biol. Chem. 263:1988;5020-5023.
14. Wang S., Deng L., Milne R.W., Tall A.R. Identification of a sequence within the C-terminal 26 amino acids of cholesteryl ester transfer protein responsible for binding a neutralizing monoclonal antibody and necessary for neutral lipid transfer activity. J. Biol. Chem. 267:1992;17487-17490.
15. Wang S., Kussie P., Deng L., Tall A.R. Defective binding of neutral lipids by a carboxyl-terminal deletion mutant of cholesteryl ester transfer protein. J. Biol. Chem. 270:1995;612-618.
16. Tall A.R. Plasma cholesteryl ester transfer protein. J. Lipid Res. 34:1993;1255-1274.
17. Zhong S.B., Sharp D.S., Grove J.S., Bruce C., Yano K., Curb J.D., Tall A.R. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Invest. 97:1996;2917-2923.
18. Hirano K., Yamashita S., Nakajima N., Arai T., Maruyama T., Yoshida Y., Ishigami M., Sakai N., Kameda-Takemura K., Matsuzawa Y. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan-marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler. Thromb. Vasc. Biol. 17:1997;1053-1059.
19. Moriyama Y., Okamura T., Inazu A., Doi M., Iso H., Mouri Y., Ishikawa Y., Suzuki H., Iida M., Koizumi J., Mabuchi H., Komachi Y. A low prevalence of coronary heart disease among subjects with increased high density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev. Med. 27:1998;659-687.
20. Patsch J.R. Triglyceride-rich lipoproteins and atherosclerosis. Atherosclerosis. 110:(Suppl.):1994;S23-S26.
21. Hill S.A., McQueen M.J. Reverse cholesterol transport - a review of the process and its clinical implications. Clin. Biochem. 30:1997;517-525.
22. Stein O., Stein Y. Atheroprotective mechanisms of HDL. Atherosclerosis. 144:1999;285-301. Review.
23. de Grooth G.J., Kuivenhoven J.A., Stalenhoef A.F., de Graaf J., Zwinderman A.H., Posma J.L., van Tol A., Kastelein J.J. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 105:2002;2159-2165.